Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) will host a virtual investor briefing on Thursday, June 11, at 10:30am AEST to provide an update on the US commercialisation of FebriDx® following FDA CLIA waiver clearance.
Director of US Sales Tommy Hall and PHASE Scientific vice president of commercial operations Bob Gergen will outline progress since CLIA waiver status was received, including the rollout of FebriDx across more than 100 healthcare locations in 18 US states.
Those sites collectively performed around 195,000 influenza tests over the past year, providing an established base for broader respiratory infection management applications.
The briefing will also cover Lumos’ expanding commercial footprint across urgent care, primary care, concierge medicine and collegiate health settings, as well as progress on reimbursement engagement with Medicare, Medicaid and private payors.
Managing director and CEO Doug Ward will also join the briefing, which will be followed by a Q&A session.
Investors can register for the webinar here: https://us02web.zoom.us/webinar/register/WN_3vSVG5koRLOJajzY8p8gJg
Lumos reports strong early uptake and reimbursement outcomes for FebriDx in US rollout
Lumos recently reported positive early progress in the US commercial rollout of its FebriDx® rapid respiratory infection test, following recent FDA CLIA waiver clearance.
The company said reimbursement performance and customer adoption were tracking positively ahead of the 2026/27 flu season, with more than 90% of submitted reimbursement claims paid to date.
Average payments have exceeded the Medicare fee schedule benchmark of US$41.38 per test.
Lumos is using the lower-volume US spring and summer testing period to build market awareness, onboard customers, progress pilot evaluations and refine reimbursement pathways in CLIA-waived settings.
“Securing CLIA waiver was a major step forward, but successful commercialisation also depends on showing that providers can implement FebriDx® routinely and receive payment for its use,” Lumos CEO Doug Ward said.
“While these reimbursement datasets are still in their infancy and not yet statistically significant, we are very pleased with the initial signals.
“They support the view that FebriDx® can be embedded into routine workflows in urgent care and primary care, particularly as providers prepare for the next flu season.”